SNIPER (ABL) -019

• Description:

  SNIPER (ABL) -019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM[1].

• UNSPSC:

  12352005

• Target:

  Bcr-Abl; SNIPERs

• Type:

  Reference compound

• Related Pathways:

  PROTAC; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sniper-abl-019.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(NC(C2=CN=C(NC3=CC(N4CCN(C(COCCOCCOCCNC([C@H](C(C5=CC=CC=C5)C6=CC=CC=C6)NC([C@H]7N(C([C@@H](NC([C@H](C)NC)=O)C8CCCCC8)=O)CCC7)=O)=O)=O)CC4)=NC(C)=N3)S2)=O)C(Cl)=CC=C1

• Molecular Formula:

  C60H77ClN12O9S

• Molecular Weight:

  1177.85

• References & Citations:

  [1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108 (8) :1657-1666.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported